glp-1 constipation lawsuit in west virginia semaglutide class action Ozempic Class Action GLP-1 Weight Loss Drugs and

While retatrutide and SAR441255 demonstrate significant potential, several important aspects must be addressed to fully optimize the clinical application of triple agonists

Future research should prioritize prospective, controlled investigations evaluating body composition trajectories in men with confirmed low testosterone initiating GLP-1 receptor agonist therapy

All had a body mass index of 30 or more

Some GLP-1 medications have demonstrated cardiovascular benefits in clinical trials (such as LEADER for liraglutide, SUSTAIN-6 for semaglutide, and REWIND for dulaglutide), and discontinuation may result in loss of these protective effects

Carrying it on can keep glucose down but raise the risk of residual gastric content